Blood Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

Published on : Jul-2017 | List of Tables : 165 | List of Figures : 57 | No. of Pages : 170 | Report Code : FACT47MR | Format : ppt pdf Excel Word

Blood cancer diagnostics can be defined as the wide range of screening & diagnosis tests associated with blood cancers such as lymphoma, leukemia and myeloma. Bone marrow examination, blood sample tests, complete blood count tests, flow cytometry, cupping therapy and genetic testing are prominent procedures in the diagnosis of blood cancer.

Increase in the prevalence of oncological diseases and technological advancements in diagnostics are positively impacting the global blood cancer diagnostics market. Focus on detecting cancer at an early stage through molecular and RNA/DNA testing can widely improve the diagnosis. As spending on healthcare witnesses a gradual increase in developing countries, the overall blood cancer diagnostics market is projected to grow at a steady rate during the forecast period 2017-2022. According to Fact.MR’s analysis, the global blood cancer diagnostics market is projected to grow at a steady CAGR during the forecast period.

Fact.MR’s report offers market analysis and forecast on the global blood cancer diagnostics market on the basis of test type. Liquid biopsy is another test type that remains widely used among end-users. Studies have shown that liquid biopsy can overcome challenges related to intra- and inter-tumor heterogeneity. The research was carried out at Harvard Medical School and Massachusetts General Hospital Cancer Center. Inclusion of liquid biopsy can help in identifying resistance alternations in patients with advanced cholangiocarcinoma. On account of growing preference for liquid biopsy, this segment is projected to increase at a CAGR of over 10% through 2022.

Market Taxonomy

Test Type

End User

CBC Tests

Hospital Associated Labs

CTC Tests

Independent Diagnostic Laboratories

Blood Protein Testing

Cancer Research Institutes

Liquid Biopsy

Others

Bone Marrow Biopsy

 

Others

 

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

For more insights, request sample of this report.

According to the report, the CBC test segment type of the global blood cancer market is valued at nearly US$ 77 million in 2017. By 2022, this is projected to grow at a healthy rate. The market in North America will remain lucrative for manufacturers throughout the forecast period. The CTC tests segment on the other hand, is anticipated to grow at a relatively higher CAGR than the CBC test segments.

Owing to accuracy and convenience of blood testing protein test type, it is anticipated that more end-use sectors will continue to use this type of testing globally. Fact.MR estimates the global blood protein testing market to rake in significant revenues during the forecast period.

By end-users, hospital associated labs account for a significant percentage of the global blood cancer diagnostics market. Valued at over US$ 136 million in 2017, the hospital associated labs segment is projected to surpass US$ 180 million in revenues by 2022. Demand from hospital associated labs segment is projected to grow at a steady CAGR during the forecast period.

Demand for blood cancer diagnostics is also significant from the independent diagnostic laboratories segment. According to Fact.MR’s research, the independent diagnostics laboratories segment is projected to grow steadily through 2022. Cancer research institutes are also a key end-user, and demand from this segment is projected to grow at healthy CAGR through 2022.

Competition Tracking

The key companies profiled in Fact.MR’s research include Abbott Laboratories, Roche Holding A.G., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Luminex Corporation, Myriad Genetics Inc., NanoString Technologies Inc, NeoGenomics Laboratories, Inc., Siemens AG, Quest Diagnostics Incorporated, Qiagen N.V., Agilent Technologies, Biotheranostics, Inc, Almac Group Limited, and GeneNews Limited.

Overall, the global blood cancer diagnostics market is anticipated to witness steady growth through 2022. The market will continue to be influenced by regulatory policies and guidelines.

Request research methodology of this report.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for blood cancer. Rising number of deaths caused by blood cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of blood cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo. The burden of controlling the incidence of blood cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.

The report on the global market for blood cancer diagnostics discusses such key factors that govern the economics of blood cancer diagnostics across the globe. Some of the key influences for the growth of global blood cancer diagnostics market include:

  • rising presence of carcinogenic elements in common consumables
  • surging exposure to toxic substances in factories & industrial settings
  • lack of awareness related to causes, symptoms, and preventive measures for blood cancer
  • high healthcare costs, deterring blood cancer patients from seeking optimum diagnosis

With growing incidence of blood cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for blood cancer. As blood cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of blood cancer.

Need for Premeditated Blood Cancer Patient Compliance 

Blood cancer patients are often riddled with confusing options for diagnosis. Choosing the right screening test can become a dilemma for the patient and his/her family. Companies manufacturing medical instruments and devices for diagnosis of blood cancer are expected to mitigate such difficulties by facilitating a well-laid patient compliance regime.

The global market for blood cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of blood cancer patients.

Key players in the global blood cancer diagnostics market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on blood cancer patients. Such cooperative efforts are of paramount importance in the global blood cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.

Blood Cancer diagnostics market – Regional Overview & Competitive Backdrop

A comprehensive section on the regional analysis of global blood cancer diagnostics market is included in the report. North America, Europe, Japan, Asia-Pacific excluding Japan (APEJ), Latin America, and Middle East & Africa are key regions into which the expansion of global blood cancer diagnostics market is studied. Developed markets with robust healthcare infrastructures are deemed lucrative for patients seeking diagnosis for blood cancer. On the other hand, higher resource availability, cheap wages, and lenient manufacturing regulations in developing regions attract the attention of manufacturers of blood cancer diagnosis instruments.

In the report, there is an elaborate section on the competitive landscape of global blood cancer diagnostics market. This part profiles key players in the global market, which includes leading manufacturers of diagnostic devices and related medical apparatus. The scalability employed in profiling these players includes criteria such as the company’s contribution to global blood cancer diagnostics market revenues, recent mergers & acquisitions involving the company, and new product launches. Through this report, companies can also understand the investment standpoint in the global blood cancer diagnostics market, which can be further inferred while taking insightful actions.

Research Methodology

Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,

  • Primary research
  • Secondary research
  • Trade research
  • Focused interviews
  • Social media analysis

Chapter 1. Global Blood Cancer Diagnostics Market - Executive Summary. 12

Chapter 2. Global Blood Cancer Diagnostics Market Overview. 14
2.1. Introduction. 14
       2.1.1. Global Blood Cancer Diagnostics Market Taxonomy. 14
       2.1.2. Global Blood Cancer Diagnostics Market Definition. 14
2.2. Global Blood Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 15
       2.2.1. Global Blood Cancer Diagnostics Market Y-o-Y Growth. 15
2.3. Global Blood Cancer Diagnostics Market Dynamics. 15
       2.3.1. Drivers. 15
       2.3.2. Restraints. 16
       2.3.3. Trends. 16
2.4. Supply Chain. 16
2.5. Epidemiology. 16
2.6. List of Distributors. 16
2.7. Average Pricing Analysis. 17
2.8. Regulations. 17
2.9. Key Participants Market Presence (Intensity Map) By Region. 17

Chapter 3. Global Blood Cancer Diagnostics Market Analysis and Forecast By Test Type. 18
3.1. Global Blood Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 18
       3.1.1. CBC Tests Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 18
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 18
                3.1.1.2. Market Share Comparison, By Region. 20
                3.1.1.3. Y-o-Y growth Comparison, By Region. 20
       3.1.2. CTC Tests Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 21
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 21
                3.1.2.2. Market Share Comparison, By Region. 23
                3.1.2.3. Y-o-Y growth Comparison, By Region. 23
       3.1.3. Blood Protein Testing Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 24
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 24
                3.1.3.2. Market Share Comparison, By Region. 26
                3.1.3.3. Y-o-Y growth Comparison, By Region. 26
       3.1.4. Liquid Biopsy Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 27
                3.1.4.1. Revenue (US$ Mn) Comparison, By Region. 27
                3.1.4.2. Market Share Comparison, By Region. 29
                3.1.4.3. Y-o-Y growth Comparison, By Region. 29
       3.1.5. Bone Marrow Biopsy Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 30
                3.1.5.1. Revenue (US$ Mn) Comparison, By Region. 30
                3.1.5.2. Market Share Comparison, By Region. 32
                3.1.5.3. Y-o-Y growth Comparison, By Region. 32
       3.1.6. Others Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 33
                3.1.6.1. Revenue (US$ Mn) Comparison, By Region. 33
                3.1.6.2. Market Share Comparison, By Region. 35
                3.1.6.3. Y-o-Y growth Comparison, By Region. 35

Chapter 4. Global Blood Cancer Diagnostics Market Analysis and Forecast By End User. 37
4.1. Global Blood Cancer Diagnostics Market Size and Forecast By End User, 2012-2022. 37
       4.1.1. Hospital Associated Labs Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 37
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region. 37
                4.1.1.2. Market Share Comparison, By Region. 39
                4.1.1.3. Y-o-Y growth Comparison, By Region. 39
       4.1.2. Independent Diagnostic Laboratories Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 40
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region. 40
                4.1.2.2. Market Share Comparison, By Region. 42
                4.1.2.3. Y-o-Y growth Comparison, By Region. 42
       4.1.3. Cancer Research Institutes Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 43
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region. 43
                4.1.3.2. Market Share Comparison, By Region. 45
                4.1.3.3. Y-o-Y growth Comparison, By Region. 45
       4.1.4. Others Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 46
                4.1.4.1. Revenue (US$ Mn) Comparison, By Region. 46
                4.1.4.2. Market Share Comparison, By Region. 48
                4.1.4.3. Y-o-Y growth Comparison, By Region. 48

Chapter 5. Global Blood Cancer Diagnostics Market Analysis and Forecast By Region. 50
5.1. Global Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 50
       5.1.1. North America Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 50
                5.1.1.1. Revenue (US$ Mn) Comparison, By Test Type. 50
                5.1.1.2. Revenue (US$ Mn) Comparison, By End User. 52
       5.1.2. Latin America Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 54
                5.1.2.1. Revenue (US$ Mn) Comparison, By Test Type. 54
                5.1.2.2. Revenue (US$ Mn) Comparison, By End User. 55
       5.1.3. Europe Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 57
                5.1.3.1. Revenue (US$ Mn) Comparison, By Test Type. 57
                5.1.3.2. Revenue (US$ Mn) Comparison, By End User. 59
       5.1.4. Japan Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 61
                5.1.4.1. Revenue (US$ Mn) Comparison, By Test Type. 61
                5.1.4.2. Revenue (US$ Mn) Comparison, By End User. 62
       5.1.5. APEJ Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 64
                5.1.5.1. Revenue (US$ Mn) Comparison, By Test Type. 64
                5.1.5.2. Revenue (US$ Mn) Comparison, By End User. 66
       5.1.6. MEA Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 67
                5.1.6.1. Revenue (US$ Mn) Comparison, By Test Type. 67
                5.1.6.2. Revenue (US$ Mn) Comparison, By End User. 69

Chapter 6. North America Blood Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 71
6.1. US Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 71
       6.1.1. Revenue (US$ Mn) Comparison, By Test Type. 71
       6.1.2. Revenue (US$ Mn) Comparison, By End User. 72
6.2. Canada Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 73
       6.2.1. Revenue (US$ Mn) Comparison, By Test Type. 73
       6.2.2. Revenue (US$ Mn) Comparison, By End User. 74

Chapter 7. Latin America Blood Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 75
7.1. Brazil Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 75
       7.1.1. Revenue (US$ Mn) Comparison, By Test Type. 75
       7.1.2. Revenue (US$ Mn) Comparison, By End User. 76
7.2. Mexico Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 77
       7.2.1. Revenue (US$ Mn) Comparison, By Test Type. 77
       7.2.2. Revenue (US$ Mn) Comparison, By End User. 78
7.3. Argentina Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 79
       7.3.1. Revenue (US$ Mn) Comparison, By Test Type. 79
       7.3.2. Revenue (US$ Mn) Comparison, By End User. 80

Chapter 8. Europe Blood Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 81
8.1. Germany Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 81
       8.1.1. Revenue (US$ Mn) Comparison, By Test Type. 81
       8.1.2. Revenue (US$ Mn) Comparison, By End User. 82
8.2. UK Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 83
       8.2.1. Revenue (US$ Mn) Comparison, By Test Type. 83
       8.2.2. Revenue (US$ Mn) Comparison, By End User. 84
8.3. France Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 85
       8.3.1. Revenue (US$ Mn) Comparison, By Test Type. 858.3.2. Revenue (US$ Mn) Comparison, By End User. 86
8.4. Spain Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 87
       8.4.1. Revenue (US$ Mn) Comparison, By Test Type. 87
       8.4.2. Revenue (US$ Mn) Comparison, By End User. 88
8.5. Italy Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 89
       8.5.1. Revenue (US$ Mn) Comparison, By Test Type. 89
       8.5.2. Revenue (US$ Mn) Comparison, By End User. 90
8.6. Nordic Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 91
       8.6.1. Revenue (US$ Mn) Comparison, By Test Type. 91
       8.6.2. Revenue (US$ Mn) Comparison, By End User. 92

Chapter 9. Japan Blood Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 93
9.1. Japan Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 93
       9.1.1. Revenue (US$ Mn) Comparison, By Test Type. 93
       9.1.2. Revenue (US$ Mn) Comparison, By End User. 94

Chapter 10. APEJ Blood Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 95
10.1. China Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 95
       10.1.1. Revenue (US$ Mn) Comparison, By Test Type. 95
       10.1.2. Revenue (US$ Mn) Comparison, By End User. 96
10.2. India Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 97
       10.2.1. Revenue (US$ Mn) Comparison, By Test Type. 97
       10.2.2. Revenue (US$ Mn) Comparison, By End User. 98
10.3. Malaysia Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 99
       10.3.1. Revenue (US$ Mn) Comparison, By Test Type. 99
       10.3.2. Revenue (US$ Mn) Comparison, By End User. 100
10.4. Thailand Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 101
       10.4.1. Revenue (US$ Mn) Comparison, By Test Type. 101
       10.4.2. Revenue (US$ Mn) Comparison, By End User. 102
10.5. Singapore Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 103
       10.5.1. Revenue (US$ Mn) Comparison, By Test Type. 103
       10.5.2. Revenue (US$ Mn) Comparison, By End User. 104
10.6. Australia Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 105
       10.6.1. Revenue (US$ Mn) Comparison, By Test Type. 105
       10.6.2. Revenue (US$ Mn) Comparison, By End User. 106

Chapter 11. MEA Blood Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 107
11.1. GCC Countries Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 107
       11.1.1. Revenue (US$ Mn) Comparison, By Test Type. 107
       11.1.2. Revenue (US$ Mn) Comparison, By End User. 108
11.2. South Africa Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 109
       11.2.1. Revenue (US$ Mn) Comparison, By Test Type. 109
       11.2.2. Revenue (US$ Mn) Comparison, By End User. 110
11.3. Nigeria Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 111
       11.3.1. Revenue (US$ Mn) Comparison, By Test Type. 111
       11.3.2. Revenue (US$ Mn) Comparison, By End User. 112
11.4. Israel Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 113
       11.4.1. Revenue (US$ Mn) Comparison, By Test Type. 113
       11.4.2. Revenue (US$ Mn) Comparison, By End User. 114

Chapter 12. Company Profiles. 115
12.1. Abbott Laboratories. 115
       12.1.1. Company Overview. 115
       12.1.2. Product Overview. 116
       12.1.3. Key Financials. 116
       12.1.4. Key Developments. 116
12.2. Roche Holding AG.. 117
       12.2.1. Company Overview. 117
       12.2.2. Product Overview. 117
       12.2.3. Key Financials. 118
12.3. Thermo Fisher Scientific Inc.. 119
       12.3.1. Company Overview. 119
       12.3.2. Product Overview. 119
       12.3.3. Key Financials. 120
       12.3.4. SWOT Analysis. 120
       12.3.5. Key Developments. 121
12.4. Laboratory Corporation Of America Holdings. 122
       12.4.1. Company Overview. 122
       12.4.2. Product Overview. 122
       12.4.3. Key Financials. 123
12.5. Luminex Corporation. 124
       12.5.1. Company Overview. 124
       12.5.2. Product Overview. 124
       12.5.3. Key Financials. 125
12.6. Myriad Genetics Inc. 126
       12.6.1. Company Overview. 126
       12.6.2. Key Financials. 127
       12.6.3. SWOT Analysis. 127
12.7. NanoString Technologies Inc. 131
       12.7.1. Company Overview. 131
       12.7.2. Product Overview. 131
       12.7.3. Key Financials. 131
12.8. NeoGenomics Laboratories, Inc.. 133
       12.8.1. Company Overview. 133
       12.8.2. Key Financials. 133
12.9. Siemens AG. 134
       12.9.1. Company Overview. 134
       12.9.2. Key Financials. 134
       12.9.3. Key Developments. 135
       12.9.4. SWOT Analysis. 135
12.10. Quest Diagnostics Incorporated. 136
       12.10.1. Company Overview. 136
       12.10.2. Product Overview. 136
       12.10.3. Key Financials. 137
       12.10.4. SWOT Analysis. 137
12.11. QIAGEN N.V.. 140
       12.11.1. Company Overview. 140
       12.11.2. Product Overview. 140
       12.11.3. Key Financials. 141
12.12. Agilent Technologies. 142
       12.12.1. Company Overview. 142
       12.12.2. Product Overview. 142
       12.12.3. Key Financials. 142
       12.12.4. Key Developments. 143
       12.12.5. SWOT Analysis. 143
12.13. Biotheranostics, Inc. 144
       12.13.1. Company Overview. 144
       12.13.2. Product Overview. 144
12.14. Almac Group Limited. 145
       12.14.1. Company Overview. 145
       12.14.2. Product Overview. 145
12.15. GeneNews Limited. 146
       12.15.1. Company Overview. 146
       12.15.2. Product Overview. 146

Chapter 13. Disclaimer and Contact information. 147

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Blood Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022